Literature DB >> 14988020

Activation of the WT1 tumor suppressor gene promoter by Pea3.

Maria Teresa Discenza1, Darryl Vaz, John A Hassell, Jerry Pelletier.   

Abstract

Gene array profiling of RNA from cells engineered to express a dominant-negative version of the ETS family member transcription factor Pea3 (polyomavirus enhancer activator 3) identified WT1 as a candidate downstream gene. Given the co-expression of WT1 and Pea3 in developing kidney and breast tissue undergoing mesenchymal to epithelial transitions, we further characterized this potential gene hierarchy. Analysis of the human WT1 promoter revealed several potential binding sites for Pea3. Pea3 transactivated the WT1 promoter in transient transfection assays and bound to specific sites within the WT1 promoter in vitro. Our results position Pea3 upstream of WT1 and define a gene hierarchy important for mesenchymal-epithelial transitions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14988020     DOI: 10.1016/S0014-5793(04)00104-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  11 in total

1.  HuR antagonizes the effect of an intronic pyrimidine-rich sequence in regulating WT1 +/-KTS isoforms.

Authors:  Hui Li; Shuai Hou; Tian Hao; Sikandar Azam; Caigang Liu; Lei Shi; Haixin Lei
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

2.  Expression and function of the Ets transcription factor pea3 during formation of zebrafish pronephros.

Authors:  Qiuxia Chen; Songming Huang; Qingshun Zhao; Ronghua Chen; Aihua Zhang
Journal:  Pediatr Nephrol       Date:  2010-12-24       Impact factor: 3.714

3.  The Wilms' tumor 1 (WT1) gene (+KTS isoform) functions with a CTE to enhance translation from an unspliced RNA with a retained intron.

Authors:  Yeou-cherng Bor; Jennifer Swartz; Avril Morrison; David Rekosh; Michael Ladomery; Marie-Louise Hammarskjöld
Journal:  Genes Dev       Date:  2006-05-31       Impact factor: 11.361

4.  Deficiency in WT1-targeting microRNA-125a leads to myeloid malignancies and urogenital abnormalities.

Authors:  N Tatsumi; N Hojo; O Yamada; M Ogawa; Y Katsura; S Kawata; E Morii; H Sakamoto; R Inaba; A Tsuda; I Fukuda; N Moriguchi; H Hasuwa; M Okabe; F Fujiki; S Nishida; H Nakajima; A Tsuboi; Y Oka; N Hosen; H Sugiyama; Y Oji
Journal:  Oncogene       Date:  2015-05-11       Impact factor: 9.867

5.  NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications.

Authors:  Anthony G Clementz; Allison Rogowski; Kinnari Pandya; Lucio Miele; Clodia Osipo
Journal:  Breast Cancer Res       Date:  2011-06-14       Impact factor: 6.466

6.  WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study.

Authors:  Wirote Netinatsunthorn; Jitti Hanprasertpong; Chavaboon Dechsukhum; Roengsak Leetanaporn; Alan Geater
Journal:  BMC Cancer       Date:  2006-04-11       Impact factor: 4.430

7.  Despite WT1 binding sites in the promoter region of human and mouse nucleoporin glycoprotein 210, WT1 does not influence expression of GP210.

Authors:  Magnus Olsson; Milton A English; Jacqueline Mason; Jonathan D Licht; Peter Ekblom
Journal:  J Negat Results Biomed       Date:  2004-12-21

8.  Pea3 transcription factors and wnt1-induced mouse mammary neoplasia.

Authors:  Rebecca Baker; Claire V Kent; Rachel A Silbermann; John A Hassell; Lawrence J T Young; Louise R Howe
Journal:  PLoS One       Date:  2010-01-22       Impact factor: 3.240

9.  PPARbeta activation inhibits melanoma cell proliferation involving repression of the Wilms' tumour suppressor WT1.

Authors:  Jean-François Michiels; Christophe Perrin; Nathalie Leccia; Daniela Massi; Paul Grimaldi; Nicole Wagner
Journal:  Pflugers Arch       Date:  2010-01-12       Impact factor: 3.657

10.  Overexpression of ETV4 is oncogenic in prostate cells through promotion of both cell proliferation and epithelial to mesenchymal transition.

Authors:  A Pellecchia; C Pescucci; E De Lorenzo; C Luceri; N Passaro; M Sica; R Notaro; M De Angioletti
Journal:  Oncogenesis       Date:  2012-07-16       Impact factor: 7.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.